ANI Pharmaceuticals, Inc. $ANIP Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC lifted its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 791.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 22,847 shares of the specialty pharmaceutical company’s stock after purchasing an additional 20,283 shares during the quarter. SG Americas Securities LLC’s holdings in ANI Pharmaceuticals were worth $2,093,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in ANI Pharmaceuticals by 9.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,505 shares of the specialty pharmaceutical company’s stock valued at $138,000 after purchasing an additional 126 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its position in shares of ANI Pharmaceuticals by 1.0% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after acquiring an additional 198 shares during the period. Thrivent Financial for Lutherans raised its stake in ANI Pharmaceuticals by 2.6% in the 2nd quarter. Thrivent Financial for Lutherans now owns 12,511 shares of the specialty pharmaceutical company’s stock worth $816,000 after acquiring an additional 321 shares during the last quarter. Legal & General Group Plc raised its stake in ANI Pharmaceuticals by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 46,712 shares of the specialty pharmaceutical company’s stock worth $3,048,000 after acquiring an additional 351 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in ANI Pharmaceuticals by 10.0% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 4,368 shares of the specialty pharmaceutical company’s stock worth $285,000 after acquiring an additional 396 shares during the period. Hedge funds and other institutional investors own 76.05% of the company’s stock.

Insiders Place Their Bets

In related news, VP Meredith Cook sold 500 shares of the company’s stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $84.33, for a total value of $42,165.00. Following the completion of the transaction, the vice president owned 74,374 shares of the company’s stock, valued at approximately $6,271,959.42. This represents a 0.67% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Renee P. Tannenbaum sold 1,800 shares of the stock in a transaction that occurred on Friday, December 5th. The stock was sold at an average price of $81.15, for a total value of $146,070.00. Following the transaction, the director owned 25,157 shares in the company, valued at $2,041,490.55. This represents a 6.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 28,101 shares of company stock valued at $2,453,063. Insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

ANIP has been the subject of several research analyst reports. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Guggenheim raised their price target on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Truist Financial upped their price objective on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a report on Thursday, October 9th. Finally, JPMorgan Chase & Co. increased their price objective on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 24th. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $102.14.

ANI Pharmaceuticals Trading Up 3.3%

ANI Pharmaceuticals stock opened at $85.03 on Thursday. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20. ANI Pharmaceuticals, Inc. has a 12 month low of $54.10 and a 12 month high of $99.50. The stock’s 50 day simple moving average is $82.22 and its two-hundred day simple moving average is $83.55. The firm has a market cap of $1.91 billion, a PE ratio of 52.17 and a beta of 0.51.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The firm had revenue of $227.81 million during the quarter, compared to analyst estimates of $211.92 million. During the same period in the previous year, the firm earned $1.34 EPS. The business’s quarterly revenue was up 53.6% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. Analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.